News Flash: D. Western Therapeutics Institute (4576 JP) - July 17, 2025

250 Views21 Jul 2025 19:37

Issuer-paid

SUMMARY

DWTI announced after the close on July 15 that it has decided to add H-1129, an in-house discovered candidate compound, to its pipeline and develop it as a treatment for corneal and conjunctival diseases caused by immune disorders.
‘Corneal and conjunctival diseases’ refers to a general term for conditions characterized by inflammation or damage to the cornea and conjunctiva.
The cornea is the dome- shaped transparent layer covering the iris, pupil and anterior chamber, which focuses and refracts light onto the retina.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream